Contribution of GPR30 for 1,25 dihydroxyvitamin D 3 protection in EAE

Sandhya Subramanian, Lisa M. Miller, Marjorie Grafe, Arthur Vandenbark, Halina Offner

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Previous studies have demonstrated that vitamin D3-mediated protection in EAE occurs only in females and is dependent on the presence of diestrus levels of 17β-estradiol (E2). To evaluate the role of estrogen receptors in vitamin D3 treatment of EAE, we compared disease severity, CNS histopathology and immunological responses in vehicle and calcitrol (1,25 dihydroxyvitamin D 3) treated WT C57BL/6 mice vs. GPR30 membrane estrogen receptor (MER) knockout mice with MOG-35-55 peptide-induced EAE. Our results demonstrated that vitamin D 3-mediated prevention of clinical signs, CNS cellular lesions and demyelination observed in WT mice was abrogated in GPR30-KO mice with EAE. Regulatory effects of vitamin D 3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 & CCR3 in spleen tissue. These results demonstrate for the first time that the MER is a key contributor to the E2-dependent effects of vitamin D 3-mediated protection in EAE.

Original languageEnglish (US)
Pages (from-to)29-35
Number of pages7
JournalMetabolic Brain Disease
Volume27
Issue number1
DOIs
StatePublished - Mar 2012

Fingerprint

Cholecalciferol
Estrogen Receptors
Membranes
Diestrus
Peptides
Central Nervous System Diseases
Demyelinating Diseases
Inbred C57BL Mouse
Knockout Mice
Interleukin-10
Estradiol
Interleukin-6
Spleen
1,25-dihydroxyvitamin D
Tissue

Keywords

  • 1,25 dihydroxyvitamin D
  • EAE
  • Estrogen
  • GPR30

ASJC Scopus subject areas

  • Clinical Neurology
  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Contribution of GPR30 for 1,25 dihydroxyvitamin D 3 protection in EAE. / Subramanian, Sandhya; Miller, Lisa M.; Grafe, Marjorie; Vandenbark, Arthur; Offner, Halina.

In: Metabolic Brain Disease, Vol. 27, No. 1, 03.2012, p. 29-35.

Research output: Contribution to journalArticle

@article{c4acdacf3eab437f83bf15a78d9c8371,
title = "Contribution of GPR30 for 1,25 dihydroxyvitamin D 3 protection in EAE",
abstract = "Previous studies have demonstrated that vitamin D3-mediated protection in EAE occurs only in females and is dependent on the presence of diestrus levels of 17β-estradiol (E2). To evaluate the role of estrogen receptors in vitamin D3 treatment of EAE, we compared disease severity, CNS histopathology and immunological responses in vehicle and calcitrol (1,25 dihydroxyvitamin D 3) treated WT C57BL/6 mice vs. GPR30 membrane estrogen receptor (MER) knockout mice with MOG-35-55 peptide-induced EAE. Our results demonstrated that vitamin D 3-mediated prevention of clinical signs, CNS cellular lesions and demyelination observed in WT mice was abrogated in GPR30-KO mice with EAE. Regulatory effects of vitamin D 3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 & CCR3 in spleen tissue. These results demonstrate for the first time that the MER is a key contributor to the E2-dependent effects of vitamin D 3-mediated protection in EAE.",
keywords = "1,25 dihydroxyvitamin D, EAE, Estrogen, GPR30",
author = "Sandhya Subramanian and Miller, {Lisa M.} and Marjorie Grafe and Arthur Vandenbark and Halina Offner",
year = "2012",
month = "3",
doi = "10.1007/s11011-011-9266-6",
language = "English (US)",
volume = "27",
pages = "29--35",
journal = "Metabolic Brain Disease",
issn = "0885-7490",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Contribution of GPR30 for 1,25 dihydroxyvitamin D 3 protection in EAE

AU - Subramanian, Sandhya

AU - Miller, Lisa M.

AU - Grafe, Marjorie

AU - Vandenbark, Arthur

AU - Offner, Halina

PY - 2012/3

Y1 - 2012/3

N2 - Previous studies have demonstrated that vitamin D3-mediated protection in EAE occurs only in females and is dependent on the presence of diestrus levels of 17β-estradiol (E2). To evaluate the role of estrogen receptors in vitamin D3 treatment of EAE, we compared disease severity, CNS histopathology and immunological responses in vehicle and calcitrol (1,25 dihydroxyvitamin D 3) treated WT C57BL/6 mice vs. GPR30 membrane estrogen receptor (MER) knockout mice with MOG-35-55 peptide-induced EAE. Our results demonstrated that vitamin D 3-mediated prevention of clinical signs, CNS cellular lesions and demyelination observed in WT mice was abrogated in GPR30-KO mice with EAE. Regulatory effects of vitamin D 3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 & CCR3 in spleen tissue. These results demonstrate for the first time that the MER is a key contributor to the E2-dependent effects of vitamin D 3-mediated protection in EAE.

AB - Previous studies have demonstrated that vitamin D3-mediated protection in EAE occurs only in females and is dependent on the presence of diestrus levels of 17β-estradiol (E2). To evaluate the role of estrogen receptors in vitamin D3 treatment of EAE, we compared disease severity, CNS histopathology and immunological responses in vehicle and calcitrol (1,25 dihydroxyvitamin D 3) treated WT C57BL/6 mice vs. GPR30 membrane estrogen receptor (MER) knockout mice with MOG-35-55 peptide-induced EAE. Our results demonstrated that vitamin D 3-mediated prevention of clinical signs, CNS cellular lesions and demyelination observed in WT mice was abrogated in GPR30-KO mice with EAE. Regulatory effects of vitamin D 3 treatment that were MER dependent included increased levels of IL-10 and IL-6 secreted by MOG peptide-reactive splenocytes and increased expression of CCL5, CCR1 & CCR3 in spleen tissue. These results demonstrate for the first time that the MER is a key contributor to the E2-dependent effects of vitamin D 3-mediated protection in EAE.

KW - 1,25 dihydroxyvitamin D

KW - EAE

KW - Estrogen

KW - GPR30

UR - http://www.scopus.com/inward/record.url?scp=84861821689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861821689&partnerID=8YFLogxK

U2 - 10.1007/s11011-011-9266-6

DO - 10.1007/s11011-011-9266-6

M3 - Article

VL - 27

SP - 29

EP - 35

JO - Metabolic Brain Disease

JF - Metabolic Brain Disease

SN - 0885-7490

IS - 1

ER -